| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
C24-Ceramide targets cellular membranes, where it induces time-dependent changes in membrane properties. As a sphingolipid, it promotes gel-phase formation and lateral segregation, contributing to membrane rigidity and reduced permeability. The elongated C24 chain enhances hydrogen-bonding potential, supporting ordered lamellar assemblies. C24-ceramide readily forms two types of gel domains with distinct properties, corresponding to different interdigitated metastable gel phases. It also promotes strong changes in vesicle shape, including domains with sharp edges and tubule-like structures.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that C24-Ceramide induces time-dependent changes in membrane properties. It promotes gel-phase formation and lateral segregation, contributing to membrane rigidity and reduced permeability. C24-ceramide readily forms two types of gel domains with distinct properties. It also promotes strong changes in vesicle shape, including domains with sharp edges and tubule-like structures. These in vitro findings support its applications in membrane biology and lipid research.
|
| ln Vivo |
In vivo studies of C24-Ceramide are limited as the compound is primarily used as a research chemical for in vitro membrane studies. As one of the most abundant naturally occurring ceramides, it plays important roles in biological membranes. Ceramides mediate many diverse biological activities in vivo. However, comprehensive in vivo pharmacological studies specifically targeting C24-Ceramide are not well documented. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro membrane assays for C24-Ceramide typically involve testing its effects on lipid membrane properties. Model membranes such as liposomes are prepared with varying concentrations of the compound. Membrane properties are assessed using techniques such as fluorescence spectroscopy, differential scanning calorimetry, and microscopy. The compound's ability to induce gel-phase formation and membrane reorganization is evaluated. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for C24-Ceramide involve culturing cells to evaluate its effects on membrane properties and cellular functions. Cells are treated with varying concentrations of the compound and membrane properties are assessed. Ceramide-mediated signaling pathways are evaluated. Cell viability is assessed using MTT or similar colorimetric assays. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
C24-Ceramide (CAS# 34435-05-7) is a sphingolipid with the molecular formula C42H83NO3 and a molecular weight of 650.11. The compound appears as a white to off-white solid with a purity of 98%+. It is stored under appropriate conditions for research use. As a lipophilic sphingolipid, it would be incorporated into membranes. Complete pharmacokinetic profiling including absorption, distribution, metabolism, and excretion would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| ADME/Pharmacokinetics |
The toxicity profile of C24-Ceramide has been evaluated in the context of its use as a research chemical. As a naturally occurring sphingolipid, it is expected to have a favorable safety profile at research concentrations. The compound has a purity of 98%+. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| Toxicity/Toxicokinetics |
C24-Ceramide (CAS# 34435-05-7) is also known as N-tetracosanoylsphingosine, lignoceric ceramide (C24:0), and C24神经酰胺. It has the molecular formula C42H83NO3 and a molecular weight of 650.11. The compound is one of the most abundant naturally occurring ceramides. C24-Ceramide is utilized in the composition of lipid membranes and induces time-dependent changes in membrane properties. It promotes gel-phase formation, membrane rigidity, and reorganization. Ceramides mediate many diverse biological activities.
|
| References | |
| Additional Infomation |
N-Tecosylsphingosine is an N-acylsphingosine in which the N-acyl group of the ceramide is designated as a tetracosyl group. It is a mouse metabolite. It is an N-acylsphingosine, Cer(d42:1), and N-(very long chain fatty acyl)sphingosine base. It is functionally related to tetracosyl acid.
|
| Molecular Formula |
C42H83NO3
|
|---|---|
| Molecular Weight |
650.11
|
| Exact Mass |
649.637
|
| CAS # |
34435-05-7
|
| Related CAS # |
C24-Ceramide (d18:1/24:0);102917-80-6;C24-Ceramide-d7;1840942-15-5
|
| PubChem CID |
5283571
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
750.0±60.0 °C at 760 mmHg
|
| Melting Point |
94-96ºC
|
| Flash Point |
407.4±32.9 °C
|
| Vapour Pressure |
0.0±5.7 mmHg at 25°C
|
| Index of Refraction |
1.479
|
| LogP |
17.59
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
38
|
| Heavy Atom Count |
46
|
| Complexity |
622
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@@H](/C=C/CCCCCCCCCCCCC)O
|
| InChi Key |
ZJVVOYPTFQEGPH-AUTSUKAISA-N
|
| InChi Code |
InChI=1S/C42H83NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-42(46)43-40(39-44)41(45)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h35,37,40-41,44-45H,3-34,36,38-39H2,1-2H3,(H,43,46)/b37-35+/t40-,41+/m0/s1
|
| Chemical Name |
N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]tetracosanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5382 mL | 7.6910 mL | 15.3820 mL | |
| 5 mM | 0.3076 mL | 1.5382 mL | 3.0764 mL | |
| 10 mM | 0.1538 mL | 0.7691 mL | 1.5382 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
